Breaking News, Collaborations & Alliances

Coronado Biosciences, Falk, OvaMed In TSO Pact

Will develop Crohn's disease drug in U.S. and Europe

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Coronado Biosciences, Inc. has signed a collaboration agreement with Dr. Falk Pharma GmbH and OvaMed GmbH for the development of TSO (Trichuris suis ova or CNDO-201) for Crohn’s disease. Falk has granted Coronado exclusive rights and licenses for certain preclinical data and clinical data from Falk’s clinical trials of TSO in Crohn’s disease, including an ongoing Phase II trial, for use in North America, South America and Japan. Coronado granted Falk exclusive rights and licen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters